Anticipate FDA feedback on clinical hold for AMR in Q2, 2025. Target IND submission for Aplastic Anemia in Q2, 2025. Report the interim data from the ongoing ITP phase 1 study in mid-2025. Anticipate finalizing the equity transfer agreement regarding Precision Autoimmune Therapeutics in Q2 2025. Upon completion of this transaction, CASI will have the sole global ownership of all indications in CID-103.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CASI: